Quantcast
Channel: Stock Blog Hub » NVO
Browsing latest articles
Browse All 46 View Live

(NVO) Novo Nordisk AS – 5 analysts raised projections in the past month

Novo Nordisk (NVO) shares are climbing on estimate revisions as the next report approaches. Company Description Novo manufactures pharmaceutical products and specializes in insulin and diabetes care....

View Article



(ZGEN) ZymoGenetics Inc Inks Licensing Deal with Novo Nordisk A/S

ZymoGenetics Inc. (ZGEN) announced recently that it has signed a deal with Novo Nordisk A/S (NVO) whereby the latter gets global rights to an antibody drug developed by ZymoGenetics to block...

View Article

(AMLN) Amylin Pharmaceuticals Impresses in Head-to-Head

Amylin Pharmaceuticals, Inc. (AMLN) recently announced positive results on its once weekly formulation of Byetta (referred to as exenatide once weekly), which is being developed in collaboration with...

View Article

(MNKD) MannKind Awaits US Food and Drug Administration Decision

The next few days will be very crucial for MannKind (MNKD). The US Food and Drug Administration (FDA) is expected to decide on the company’s lead product candidate Afresa, which is an inhaled insulin...

View Article

(MNKD) MannKind Corporation Gets FDA Setback

Recently, MannKind Corporation (MNKD) received a setback regarding the approval of its much awaited product Afrezza (formerly known as Afresa) ? inhaled insulin for the treatment of type I and type II...

View Article


(NVO) Novo Nordisk Earns US Food and Drug Administration for Diabetes Treatment

In a major breakthrough, Denmark based Novo Nordisk (NVO) received US Food and Drug Administration (FDA) approval for Victoza (liraglutide), a once-daily injection for the treatment of type II diabetes...

View Article

(AMLN) Amylin Pharmaceuticals’ Drug Approval Delayed

The US Food and Drug Administration (FDA) recently issued a complete response letter delaying the approval of Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Co. (LLY) and Alkermes, Inc.’s (ALKS)...

View Article

(NVO) Novo Nordisk’s Victoza Proves More Effective

Recently, results from Novo Nordisk’s (NVO) LEAD 6 extension study was published in Diabetes Care. The study aimed at evaluating the efficacy and safety of switching from Amylin Pharmaceuticals (AMLN)...

View Article


(BMY) Bristol-Myers Squibb Reports Encouraging Diabetes Therapy Data

Recently, Bristol-Myers Squibb Co. (BMY) reported encouraging results from a late-stage study evaluating the combination therapy of Onglyza (saxagliptin) and metformin in patients suffering from type...

View Article


(ALKS) Alkermes, Amylin Pharmaceuticals, and Eli Lilly See Encouraging Data...

Recently Alkermes Inc. (ALKS), Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), the co-developers of type II diabetes candidate Bydureon (exenatide once weekly), presented pooled...

View Article

(ALKS) Alkermes Earnings Report Shows Revenues Dipped

Alkermes Inc.’s (ALKS) first-quarter fiscal 2011 net loss of  14 cents per share compared unfavorably with the year-ago loss of 2 cents per share. The Zacks Consensus Estimate was a loss of 14 cents...

View Article

(BMY) Bristol-Myers Squibb Company Diabetes Drug Candidate Encourages

Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, international, randomized,...

View Article

(BMY) Bristol-Myers Squibb Trial Presents Encouraging Data

Recently, Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized,...

View Article


(BMY) Bristol-Myers Squibb’s Pipeline Advances

Bristol-Myers Squibb Company’s (BMY) pipeline received a boost when its type II diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group,...

View Article

(AMLN) Amylin Pharmaceuticals Reports Wider Loss

Amylin Pharmaceuticals (AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents....

View Article


(AMLN) Amylin Pharmaceuticals Releases Disappointing Data

Shares of Amylin Pharmaceuticals, Inc. (AMLN) lost more than 25% when the company released disappointing data on Bydureon (exenatide once-weekly) from a head-to-head study. Bydureon failed to achieve...

View Article

(AMLN) Amylin Pharmaceuticals, Eli Lilly, and Alkermes Get Positive Opinion...

Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received good news regarding their pipeline candidate, Bydureon (exenatide...

View Article


(AMLN) Amylin Pharmaceuticals, Partners Eli Lilly and Alkermes Learn Bydureon...

Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received a boost with the European Commission granting marketing authorization to...

View Article

(NVO) Novo Nordisk Presents Diabetes Study Data

Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human...

View Article

(NVO) Novo Nordisk Presents Late Stage Degludec Data

Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia...

View Article

(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares

We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs...

View Article


(NVO) Novo Nordisk Data Presented at European Association for the Study of...

Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at...

View Article


(AMLN) Amylin Pharmaceuticals Posts Lower Loss

Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents....

View Article

(ALKS) Risk-Reward Balanced at Alkermes

We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00. Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was...

View Article

(LLY) Eli Lilly and Company GLP-1 Agonist Delivers

Eli Lilly and Company (LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study....

View Article


(ALKS) Back to Neutral on Alkermes

We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at current levels. Our target price is $20.00. The stock carries a Zacks #3 Rank (Hold...

View Article

(AZN) AstraZeneca’s Forxiga Gets EU Approval

Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga (dapagliflozin) has received European approval. The European Commission (EC) approved...

View Article

(SNY) Sanofi’s Lyxumia Gets Approval From Committee for Medicinal Products...

Sanofi (SNY) recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of its diabetes candidate, Lyxumia...

View Article

(AZN) AstraZeneca’s RA Drug Disappoints

AstraZeneca (AZN) and its partner Rigel Pharmaceuticals (RIGL) recently announced top-line data from the phase IIb OSKIRA-4 study evaluating the use of oral fostamatinib for rheumatoid arthritis (RA)....

View Article



(CHMP) Isis Pharmaceuticals’ Kynamro Earns Negative Report From European...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend the approval of Isis Pharmaceuticals Inc. (ISIS) and partner Genzyme’s, a...

View Article

(AZN) AstraZeneca Gets Positive News From Court

AstraZeneca (AZN) recently received some positive news when the Court of Appeals for the Federal Circuit maintained an earlier ruling that the US substance patent (RE37, 314) related to Crestor...

View Article

(MRK) Merck Ties Up with GE Healthcare

Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging agent [18F (flutemetamol)] in the development of Merck’s Alzheimer’s disease...

View Article

(GSK) GlaxoSmithKline Anthrax Drug Gets FDA Nod

GlaxoSmithKline (GSK) recently announced that its inhalation anthrax candidate, raxibacumab, has received US Food and Drug Administration (FDA) approval. Raxibacumab was approved for inhalational...

View Article


(NVO) Novo Nordisk’s Ryzodeg Approved in Japan

Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg (insulin degludec/insulin aspart). Ryzodeg was submitted for regulatory...

View Article

(BMY) Takeda Pharmaceutical Company Limited Terminates Amylin Agreement

Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, Inc., a wholly-owned subsidiary of Bristol-Myers...

View Article

(SNY) Sanofi Shares Remain Neutral

We are maintaining our Neutral recommendation on Sanofi (SNY). The stock carries a Zacks #3 Rank (Hold) in the short run. Sanofi reported third quarter 2012 business earnings of $1.05 per ADS, above...

View Article


(ABT) AbbVie Provides 2013 Outlook

AbbVie (ABBV) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott...

View Article


(SNY) Sanofi’s Diabetes Drug Gets EU Nod

Recently, Sanofi (SNY) received encouraging news with the European Commission (EC) approving its diabetes candidate, Lyxumia (lixisenatide). The EC cleared Lyxumia for glycemic control in patients,...

View Article

(AGN) Allergan Earnings Miss but Guidance Tops

Allergan, Inc. (AGN) reported fourth quarter 2012 earnings of $1.15 per share, missing the Zacks Consensus Estimate of $1.19 per share. While earnings increased 15.0% from the year-ago quarter,...

View Article

(SNY) Sanofi Diabetes Drug Under FDA Review

Sanofi (SNY) recently announced that the US Food and Drug Administration (FDA) has accepted the marketing application of its type II diabetes candidate, lixisenatide. The company is looking to get...

View Article

(AZN) AstraZeneca to Revamp Research and Development Structure

AstraZeneca (AZN) recently announced that it plans to initiate strategic reforms in its research and development (R&D) segment. As per proposed plans, the company’s R&D activities will be...

View Article


(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s...

View Article

(SNY) Sanofi/Transgene Inks Immunotherapy Deal

Sanofi (SNY) recently entered into a collaboration Transgene for the production of immunotherapy products and creating of an industrial platform for the same. The platform will include Transgene’s...

View Article


(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate

Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III studies (AWARD-2...

View Article

(NVO) Novo Nordisk A/S – Emisphere Technologies Modify Deal

Novo Nordisk A/S (NVO) and Emisphere Technologies, Inc. (EMIS) recently announced that they have modified their agreement for the development and commercialization of oral formulations of Novo...

View Article


(NVO) Novo Nordisk’s N9-GP See Positive Test Results

Novo Nordisk (NVO) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study. Paradigm 2 evaluated N9-GP, a long-acting FIX derivative, for on-demand or...

View Article
Browsing latest articles
Browse All 46 View Live




Latest Images